Yi Ban

Has grant

Assistant Professor of Research

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Lung cancer microenvironmnet

Open Date:

Close Date:

Articles (2)

Understanding therapy resistance requires deconvolving heterogeneous cell populations and tracking clonal trajectories. While CRISPR-based cellular barcoding is powerful for lineage tracing, many platforms suffer from low efficiency and limited compatibility with single-cell transcriptomics. We developed Oligo-CALL (Oligonucleotide-inducible CRISPR transcriptional activator–Assisted Lineage Labeling), an advanced barcoding system enabling precise lineage tracing, live clone isolation, and seamless integration with single-cell RNA sequencing. Applied to lung cancer cells treated with a KRAS G12C inhibitor, Oligo-CALL identified clones consistently enriched posttreatment, supporting a model of predestined resistance. Oligo-CALL achieved >95% efficiency in linking lineage identity to transcriptomes, uncovering diverse clone-specific pathways with underlying resistance. Paired analysis of barcode-matched clones from naïve and resistant populations revealed transient and fixed resistance phenotypes. Notably, DNA repair pathways are recurrently altered in resistant clones, and inhibition of poly(adenosine 5′-diphosphate–ribose) polymerase synergizes with KRAS G12C inhibition to overcome resistance. Together, Oligo-CALL provides a versatile platform for dissecting lineage evolution and molecular dynamics of targeted therapy resistance.

Year:

2025

Non–small lung cancers (NSCLC) frequently (∼30%) harbor KRAS driver mutations, half of which are KRAS G12C . KRAS -mutant NSCLC with comutated STK11 and/or KEAP1 is particularly refractory to conventional, targeted, and immune therapy. Development of KRAS G12C inhibitors (G12Ci) provided a major therapeutic advance, but resistance still limits their efficacy. To identify genes whose deletion augments efficacy of the G12Cis adagrasib (MRTX-849) or adagrasib plus TNO155 (SHP2i), we performed genome-wide CRISPR/Cas9 screens on KRAS/STK11 -mutant NSCLC lines. Recurrent, potentially targetable, synthetic lethal (SL) genes were identified, including serine–threonine kinases, tRNA-modifying and proteoglycan synthesis enzymes, and YAP/TAZ/TEAD pathway components. Several SL genes were confirmed by siRNA/shRNA experiments, and the YAP/TAZ/TEAD pathway was extensively validated in vitro and in mice. Mechanistic studies showed that G12Ci treatment induced gene expression of RHO paralogs and activators, increased RHOA activation, and evoked ROCK-dependent nuclear translocation of YAP. Mice and patients with acquired G12Ci- or G12Ci/SHP2i-resistant tumors showed strong overlap with SL pathways, arguing for the relevance of the screen results. These findings provide a landscape of potential targets for future combination strategies, some of which can be tested rapidly in the clinic. Significance: Identification of synthetic lethal genes with KRAS G12C using genome-wide CRISPR/Cas9 screening and credentialing of the ability of TEAD inhibition to enhance KRAS G12C efficacy provides a roadmap for combination strategies. See related commentary by Johnson and Haigis, p. 4005

Year:

2024

Collaborators (7)

Wenchao Lu

Principle Investigator

Stanford University

UNITED STATES
View details

Dingcheng Gao

Assistant Professor

Weill Cornell Medicine

UNITED STATES
View details

Michela Ranieri

Senior Research Scientist

NYU Langone Health

UNITED STATES
View details

Benjamin G Neel

NYU Langone Medical Center

UNITED STATES
View details

Igor Dolgalev

NYU School of Medicine

UNITED STATES
View details

Nathanael S. Gray

Stanford University

UNITED STATES
View details

Kwok-Kin Wong

NYU Langone Medical Center

UNITED STATES
View details